ArticleFrontiers in pharmacology2026
Heterogeneity of thromboembolic risk across ALK inhibitors: a retrospective real-world study identifying crizotinib-specific signals and high-risk subpopulations.
Rong Hu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.